Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 2Myeloid 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 69Nivolumab 57Ipilimumab 36Specimen Handling 32Magnetic Resonance Spectroscopy 25Cyclophosphamide 23Biopsy 18cemiplimab 14fludarabine 13relatlimab 11binimetinib 11Opdualag 11CTLA-4 Antigen 11trametinib 10fludarabine phosphate 10Radiosurgery 10avelumab 9Radiotherapy 9lifileucel 8dabrafenib 8Blood Specimen Collection 8atezolizumab 7aldesleukin 7Paclitaxel 7encorafenib 6X-Rays 6Standard of Care 6Interleukin-2 6Immunoglobulin G 6HhAntag691 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
IFL protocol × Dermatologic × 90 days × Clear all
NCT00959647 2026-05-08

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Genentech, Inc.

Phase 2 Completed
19 enrolled 10 charts
DermatologicGastrointestinalGynecologic

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡